TipRanks
Moderna (IT:1MRNA)
:1MRNA
Italy Market
1MRNA
Moderna
RESEARCH TOOLSreports

Moderna (1MRNA) Stock Forecast & Price Target

11 Followers
See the Price Targets and Ratings of:

1MRNA Analyst Ratings

Hold
20Ratings
Hold
3 Buy
14 Hold
3 Sell
Based on 20 analysts giving stock ratings to
Moderna
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

1MRNA Stock 12 Month Forecast

Average Price Target

€95.38
▼(-24.93% Downside)
Based on 20 Wall Street analysts offering 12 month price targets for Moderna in the last 3 months. The average price target is €95.38 with a high forecast of €160.65 and a low forecast of €35.70. The average price target represents a -24.93% change from the last price of €127.06.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"19":"€19","58":"€58","97":"€97","136":"€136","175":"€175"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":160.6507434,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€160.65</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":95.37894135933334,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€95.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35.7001652,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€35.70</span>\n  </div></div>","useHTML":true}}],"tickPositions":[19,58,97,136,175],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,174,172.97313410769232,171.9462682153846,170.91940232307692,169.89253643076924,168.86567053846153,167.83880464615385,166.81193875384616,165.78507286153848,164.75820696923077,163.7313410769231,162.7044751846154,161.6776092923077,{"y":160.6507434,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,174,167.95222625841026,161.90445251682053,155.85667877523076,149.80890503364103,143.7611312920513,137.71335755046155,131.66558380887182,125.61781006728205,119.57003632569231,113.52226258410258,107.47448884251283,101.42671510092309,{"y":95.37894135933334,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,174,163.36155116923078,152.72310233846153,142.0846535076923,131.4462046769231,120.80775584615385,110.16930701538462,99.5308581846154,88.89240935384616,78.25396052307693,67.6155116923077,56.97706286153847,46.338614030769236,{"y":35.7001652,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":24.07,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":23.525,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 41, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":20.96,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 44, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.24,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 47, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":36.805,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 48, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":45.565,"date":1772323200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 49, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":43.685,"date":1775001600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":40.275,"date":1777593600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":39.01,"date":1780272000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":64.02,"date":1782864000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 43, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":49.08,"date":1785542400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 44, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":127,"date":1788220800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":174,"date":1790812800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€160.65Average Price Target€95.38Lowest Price Target€35.70
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on IT:1MRNA
Alec Stranahan
Bank of America Securities
Bank of America Securities
―
Hold
―
Reiterated
10/09/26
Moderna price target raised to $200 from $170 at BofAModerna price target raised to $200 from $170 at BofA
RBC Capital Analyst forecast on IT:1MRNA
Luca Issi
RBC Capital
RBC Capital
€116.03
Hold
-8.68%
Downside
Reiterated
10/08/26
RBC Capital Remains a Hold on Moderna (MRNA)
Morgan Stanley Analyst forecast on IT:1MRNA
Terence Flynn
Morgan Stanley
Morgan Stanley
€84.79
Hold
-33.27%
Downside
Assigned
10/07/26
Moderna (MRNA) Gets a Hold from Morgan Stanley
Citi Analyst forecast on IT:1MRNA
Geoff Meacham
Citi
Citi
€53.55→€71.4
Sell
-43.81%
Downside
Downgraded
10/01/26
Moderna downgraded to Sell from Neutral at CitiModerna downgraded to Sell from Neutral at Citi
J.P. Morgan Analyst forecast on IT:1MRNA
Jessica Fye
J.P. Morgan
J.P. Morgan
―
Sell
―
Reiterated
09/28/26
Analysts Offer Insights on Healthcare Companies: Inventiva (NASDAQ: IVA) and Moderna (NASDAQ: MRNA)
Bernstein Analyst forecast on IT:1MRNA
Courtney Breen
Bernstein
Bernstein
€40.16
Hold
-68.39%
Downside
Reiterated
09/24/26
Moderna (MRNA) Receives a Hold from Bernstein
Jefferies Analyst forecast on IT:1MRNA
Andrew Tsai
Jefferies
Jefferies
€53.55→€133.88
Hold
5.36%
Upside
Reiterated
09/22/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pyxis Oncology (NASDAQ: PYXS), Moderna (NASDAQ: MRNA) and Eli Lilly & Co (NYSE: LLY)
Evercore ISI Analyst forecast on IT:1MRNA
Cory Kasimov
Evercore ISI
Evercore ISI
€71.4
Hold
-43.81%
Downside
Reiterated
09/11/26
Evercore ISI Sticks to Its Hold Rating for Moderna (MRNA)
DBS Analyst forecast on IT:1MRNA
Nico Chen
DBS
DBS
€133.88
Hold
5.36%
Upside
Reiterated
09/11/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Moderna (NASDAQ: MRNA) and BioNano Genomics (NASDAQ: BNGO)
Berenberg Bank Analyst forecast on IT:1MRNA
Harry Gillis
Berenberg Bank
Berenberg Bank
€40.16→€89.25
Hold
-29.76%
Downside
Reiterated
09/10/26
Analysts Conflicted on These Healthcare Names: Moderna (NASDAQ: MRNA), Merck & Company (NYSE: MRK) and Pacific Biosciences (NASDAQ: PACB)
Rothschild & Co Redburn Analyst forecast on IT:1MRNA
Simon Baker CFA
Rothschild & Co Redburn
Rothschild & Co Redburn
€35.7→€72.29
Sell
-43.10%
Downside
Downgraded
09/03/26
Moderna downgraded to Sell from Neutral at Rothschild & Co RedburnModerna downgraded to Sell from Neutral at Rothschild & Co Redburn
Argus Research Analyst forecast on IT:1MRNA
Jasper Hellweg
Argus Research
Argus Research
€160.65
Buy
26.44%
Upside
Upgraded
08/27/26
Moderna upgraded to Buy from Hold at ArgusModerna upgraded to Buy from Hold at Argus
Wolfe Research Analyst forecast on IT:1MRNA
Alexandria Hammond
Wolfe Research
Wolfe Research
―
Hold
―
Upgraded
08/25/26
Moderna upgraded to Peer Perform from Underperform at Wolfe ResearchModerna upgraded to Peer Perform from Underperform at Wolfe Research
Barclays Analyst forecast on IT:1MRNA
Eliana Merle
Barclays
Barclays
€42.84→€111.56
Hold
-12.20%
Downside
Reiterated
08/24/26
Moderna price target raised to $125 from $48 at BarclaysModerna price target raised to $125 from $48 at Barclays
UBS Analyst forecast on IT:1MRNA
Michael Yee
UBS
UBS
€44.63→€133.88
Hold
5.36%
Upside
Reiterated
08/20/26
Moderna price target raised to $150 from $50 at UBSModerna price target raised to $150 from $50 at UBS
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on IT:1MRNA
Alec Stranahan
Bank of America Securities
Bank of America Securities
―
Hold
―
Reiterated
10/09/26
Moderna price target raised to $200 from $170 at BofAModerna price target raised to $200 from $170 at BofA
RBC Capital Analyst forecast on IT:1MRNA
Luca Issi
RBC Capital
RBC Capital
€116.03
Hold
-8.68%
Downside
Reiterated
10/08/26
RBC Capital Remains a Hold on Moderna (MRNA)
Morgan Stanley Analyst forecast on IT:1MRNA
Terence Flynn
Morgan Stanley
Morgan Stanley
€84.79
Hold
-33.27%
Downside
Assigned
10/07/26
Moderna (MRNA) Gets a Hold from Morgan Stanley
Citi Analyst forecast on IT:1MRNA
Geoff Meacham
Citi
Citi
€53.55→€71.4
Sell
-43.81%
Downside
Downgraded
10/01/26
Moderna downgraded to Sell from Neutral at CitiModerna downgraded to Sell from Neutral at Citi
J.P. Morgan Analyst forecast on IT:1MRNA
Jessica Fye
J.P. Morgan
J.P. Morgan
―
Sell
―
Reiterated
09/28/26
Analysts Offer Insights on Healthcare Companies: Inventiva (NASDAQ: IVA) and Moderna (NASDAQ: MRNA)
Bernstein Analyst forecast on IT:1MRNA
Courtney Breen
Bernstein
Bernstein
€40.16
Hold
-68.39%
Downside
Reiterated
09/24/26
Moderna (MRNA) Receives a Hold from Bernstein
Jefferies Analyst forecast on IT:1MRNA
Andrew Tsai
Jefferies
Jefferies
€53.55→€133.88
Hold
5.36%
Upside
Reiterated
09/22/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pyxis Oncology (NASDAQ: PYXS), Moderna (NASDAQ: MRNA) and Eli Lilly & Co (NYSE: LLY)
Evercore ISI Analyst forecast on IT:1MRNA
Cory Kasimov
Evercore ISI
Evercore ISI
€71.4
Hold
-43.81%
Downside
Reiterated
09/11/26
Evercore ISI Sticks to Its Hold Rating for Moderna (MRNA)
DBS Analyst forecast on IT:1MRNA
Nico Chen
DBS
DBS
€133.88
Hold
5.36%
Upside
Reiterated
09/11/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Moderna (NASDAQ: MRNA) and BioNano Genomics (NASDAQ: BNGO)
Berenberg Bank Analyst forecast on IT:1MRNA
Harry Gillis
Berenberg Bank
Berenberg Bank
€40.16→€89.25
Hold
-29.76%
Downside
Reiterated
09/10/26
Analysts Conflicted on These Healthcare Names: Moderna (NASDAQ: MRNA), Merck & Company (NYSE: MRK) and Pacific Biosciences (NASDAQ: PACB)
Rothschild & Co Redburn Analyst forecast on IT:1MRNA
Simon Baker CFA
Rothschild & Co Redburn
Rothschild & Co Redburn
€35.7→€72.29
Sell
-43.10%
Downside
Downgraded
09/03/26
Moderna downgraded to Sell from Neutral at Rothschild & Co RedburnModerna downgraded to Sell from Neutral at Rothschild & Co Redburn
Argus Research Analyst forecast on IT:1MRNA
Jasper Hellweg
Argus Research
Argus Research
€160.65
Buy
26.44%
Upside
Upgraded
08/27/26
Moderna upgraded to Buy from Hold at ArgusModerna upgraded to Buy from Hold at Argus
Wolfe Research Analyst forecast on IT:1MRNA
Alexandria Hammond
Wolfe Research
Wolfe Research
―
Hold
―
Upgraded
08/25/26
Moderna upgraded to Peer Perform from Underperform at Wolfe ResearchModerna upgraded to Peer Perform from Underperform at Wolfe Research
Barclays Analyst forecast on IT:1MRNA
Eliana Merle
Barclays
Barclays
€42.84→€111.56
Hold
-12.20%
Downside
Reiterated
08/24/26
Moderna price target raised to $125 from $48 at BarclaysModerna price target raised to $125 from $48 at Barclays
UBS Analyst forecast on IT:1MRNA
Michael Yee
UBS
UBS
€44.63→€133.88
Hold
5.36%
Upside
Reiterated
08/20/26
Moderna price target raised to $150 from $50 at UBSModerna price target raised to $150 from $50 at UBS
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
IMUXImmunic
REPLReplimune Group
OVIDOvid Therapeutics
CELCCelcuity
ARDXArdelyx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Moderna

3 Months
Mani ForooharLeerink Partners
Success Rate
29/49 ratings generated profit
59%
Average Return
-10.15%
Copying Mani Foroohar's trades and holding each position for 3 Months would result in 59.18% of your transactions generating a profit, with an average return of -10.15% per trade.
1 Year
Mani ForooharLeerink Partners
Success Rate
32/49 ratings generated profit
65%
Average Return
-56.60%
Copying Mani Foroohar's trades and holding each position for 1 Year would result in 65.31% of your transactions generating a profit, with an average return of -56.60% per trade.
2 Years
Mani ForooharLeerink Partners
Success Rate
33/49 ratings generated profit
67%
Average Return
-106.90%
Copying Mani Foroohar's trades and holding each position for 2 Years would result in 67.35% of your transactions generating a profit, with an average return of -106.90% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1MRNA Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
0
0
0
0
0
Buy
3
3
5
4
4
Hold
42
43
44
31
24
Sell
12
11
9
5
4
Strong Sell
0
1
1
1
1
total
57
58
59
41
33
In the current month, 1MRNA has received 4 Buy Ratings, 24 Hold Ratings, and 5 Sell Ratings. 1MRNA average Analyst price target in the past 3 months is 95.38.
Each month's total comprises the sum of three months' worth of ratings.

1MRNA Financial Forecast

1MRNA Earnings Forecast

Next quarter’s earnings estimate for 1MRNA is -€0.98 with a range of -€1.41 to -€0.47. The previous quarter’s EPS was -€1.76. 1MRNA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 1MRNA has Performed in-line its overall industry.
Next quarter’s earnings estimate for 1MRNA is -€0.98 with a range of -€1.41 to -€0.47. The previous quarter’s EPS was -€1.76. 1MRNA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 1MRNA has Performed in-line its overall industry.

1MRNA Sales Forecast

Next quarter’s sales forecast for 1MRNA is €796.47M with a range of €746.34M to €1.00B. The previous quarter’s sales results were €129.41M. 1MRNA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 1MRNA has Performed in-line its overall industry.
Next quarter’s sales forecast for 1MRNA is €796.47M with a range of €746.34M to €1.00B. The previous quarter’s sales results were €129.41M. 1MRNA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 1MRNA has Performed in-line its overall industry.

1MRNA Stock Forecast FAQ

What is IT:1MRNA’s average 12-month price target, according to analysts?
Based on analyst ratings, Moderna’s 12-month average price target is 95.38.
    What is IT:1MRNA’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for IT:1MRNA, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Moderna a Buy, Sell or Hold?
        Moderna has a consensus rating of Hold, which is based on 3 buy ratings, 14 hold ratings and 3 sell ratings.
          What is Moderna’s share price target?
          The average share price target for Moderna is 95.38. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is €160.65 ,and the lowest forecast is €35.70. The average share price target represents -24.93% Decrease from the current price of €127.06.
            What do analysts say about Moderna?
            Moderna’s analyst rating consensus is a Hold. This is based on the ratings of 20 Wall Streets Analysts.
              How can I buy shares of Moderna?
              To buy shares of IT:1MRNA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.